14th Annual North Carolina Research Triangle Pulmonary Hypertension Symposium

Registration Fees to attend in-person*
​​​​*Registration fees include all symposium materials, breakfast, lunch and breaks.

• $195: Physicians, Industry Representatives
• $60: Non-Physician Clinicians, Allied Health, Residents, and Fellows

Registration for the Enduring Content

• Registration for the enduring content is complimentary but required.

Accommodations

A block of rooms has been reserved at the Durham Marriott City Center, 201 Foster Street, Durham, NC 27701. Rooms are $199 per night, plus applicable taxes. The room block will be held until Friday, October 14, 2022 but may sell out prior to this date. To reserve your room at the conference rate, please call Marriott Reservations at 866-792-9206 and reference the PH Symposium November 2022 group. Reservations may also be made online.

This activity has been planned and implemented by the Duke University Health System Department of Clinical Education & Professional Development for the advancement of patient care. In support of improving patient care, the Duke University Health System Department of Clinical Education & Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.

Category 1: Duke University Health System Department of Clinical Education and Professional Development designates this activity for a maximum of 6 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nurse CE: Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 6 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.

Pharmacists: Duke University Health System Department of Clinical Education and Professional Development designates this activity for a maximum of 6 ACPE credit hours. Universal Activity Number: JA0000655-0000-22-150-H04-P

The overall goal of the 14^th Annual North Carolina Research Triangle Pulmonary Hypertension Symposium is to provide education related to this challenging field on appropriate screening, diagnostic procedures, proper treatment choices, and timing in advancement of care to pulmonary hypertension specialty centers. Our local and invited keynote faculty will incorporate several case-based discussions with Q&A to provide their experience on the complexity of diagnosis, management, treatment, and successful referral of PAH patients. The symposium will provide a robust forum for interactive discussion so that health care providers in attendance can gain knowledge and reinforcement of appropriate care practices that can be put into practice.

H. James Ford, MD
Associate Professor of Medicine
Director, Pulmonary Hypertension Program
Co-Medical Director, UNC Pulmonary Clinics
Division of Pulmonary and Critical Care Medicine
University of North Carolina at Chapel Hill 

Terry Fortin, MD, MS
Associate Professor of Medicine
Co-Director, Pulmonary Vascular Disease Center
Division of Cardiology
Duke University Medical Center  

Mazen Al-Qadi, MD
Assistant Professor of Medicine
Division of Pulmonary Diseases and Critical Care Medicine
University of North Carolina at Chapel Hill
 

William Auger, MD
Adjunct Professor in the Department of Medicine
Duke University
 

Erika Berman Rosenzweig, MD
Director, Pulmonary Hypertension Center
Columbia University Medical Center/NewYork-Presbyterian Hospital

Nicholas Hill, MD
Chief, Pulmonary, Critical Care and Sleep Division
Professor, Tufts University School of Medicine

Richard Krasuski, MD
Professor of Medicine
Division of Cardiology
Duke University Medical Center 

Tim Lahm, MD
Professor, Division of Pulmonary, Critical Care and Sleep Medicine
Department of Medicine
National Jewish Health

Barbara LeVarge, MD
Assistant Professor of Medicine
Associate Director, Pulmonary Hypertension Program
Division of Pulmonary Diseases and Critical Care Medicine
University of North Carolina at Chapel Hill

Sudarshan Rajagopal, MD, PhD
Associate Professor of Medicine
Co-Director, Duke Pulmonary Vascular Disease Center 
Division of Cardiology 
Duke University Medical Center

Lisa Rose-Jones, MD
Associate Professor of Medicine, Division of Cardiology
Advanced Heart Failure/Cardiac Transplantation & Pulmonary Hypertension
Director, Training Program in Cardiovascular Disease
University of North Carolina at Chapel Hill

Oksana Shlobin, MD
Director of Education, Inova Advanced Lung Disease and Transplant Program
Director, Inova Pulmonary Vascular Disease Program
Inova Fairfax Hospital

Jordan Whitson, MD
Assistant Professor of Medicine
Division of Pulmonary, Allergy and Critical Care Medicine
Duke University Medical Center

This program is designed to meet the continuing education (CE) needs of pulmonologists, cardiologists, nurses, pharmacists, and other allied healthcare professionals involved in the treatment of pulmonary hypertension.

• Describe classification of Pulmonary Hypertension, according to the World Symposium classifications and including updates from the 6^th World Symposium, as well as the treatment options with respect to PAH-specific therapies.
• Lung/Heart-Lung Transplantation is used when PH medications fail. Explain which patients are candidates and the time frame to consider this option.  Describe pre- and peri-transplant process.
• Pulmonary arterial hypertension is treatable but not curable at this time. New medications and pathways are actively being investigated for use in pulmonary arterial hypertension. Recognize these newer medications/pathways and applications of these.
• Pulmonary arterial hypertension is a progressive disease, and it is imperative to continually assess disease progression and risk stratification. Examine Risk Calculators and Profiles to help initiate ideal up-front therapy and further adjust medications throughout the care period.
• While we are fortunate to have available multiple medications over the last 10 to 20 years, the treatments options have become more complex. Discuss combination therapy and changing therapies in response to Insurance pressures, lack of efficacy, and side effects.
• Up to 70% of people with pulmonary arterial hypertension are women. Describe the differences in gender in terms of risk, and response to therapy.
• WHO Group 3 Pulmonary Hypertension related to lung disease is undergoing resurgence of interest. Explain who is a candidate for therapy and when to initiate.
• Congenital heart disease associated PAH is part of the WHO Group 1 classification. Recognize treatment and care specific to this population.
• Recognize and distinguish similar disease processes that may or may not respond to Pulmonary Arterial Hypertension specific therapy. These in part include PH associated with congenital heart disease, parenchymal lung disease, left heart and lung disease as well as liver disease. Cases will afford examples to think about the intricacies of these issues in patient care.

All cancellation requests must be submitted in writing to Christy Darnell via email (christy.darnell@duke.edu). There will be no refunds if cancellations are made after October 5, 2022.  All plans and logistics are subject to change pending conditions of the COVID pandemic. The symposium will be held as long as COVID conditions allow us to meet in-person while following appropriate COVID protocol. The symposium is subject to going to a virtual format based on what COVID trends are nearer to the date of the symposium.

To complete all course requirements and claim continuing education credits, please do the following:

• Receive email from Duke CME office next week with link to the course evaluation.
• Complete the course evaluation.
• Attest to your hours of completion.
• Download your certificate.